At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses highlights from the Thirteenth International Kidney Cancer Symposium.
This meeting provides a forum for a varied audience with an interest in renal cell carcionoma (RCC) to exchange information that will help direct future research. The new immunotherapies that target the immune basis of cancer may have clinical applicability in both clear cell and non-clear cell RCC. It is also important to target the unique components of the RCC subtypes. Patients are encouraged to learn about clinical trials and participate if appropriate.